J&J suffers sales dip in Q2 2012

Published: 17-Jul-2012

But international sales of oral care and baby care products contributed positively


Johnson & Johnson has announced sales of $16.5bn for the second quarter of 2012, down 0.7% compared with the prior year period. Net earnings and diluted earnings per share were $1.4bn and $0.50 respectively.

But while the company’s pharmaceuticals business witnessed sales growth of 0.9% to $6.3bn, consumer sales were $3.6bn, representing a decrease of 4.6%. This was largely due to the negative impact of foreign currency said the company, which added that positive contributors to operational results included international sales of oral care products and baby care products, as well as Neutrogena skin care products.

J&J has adjusted its earnings guidance for full year 2012 to $5.00-$5.07 per share.

You may also like